Orchid Pharma shines on getting nod from USFDA for Risedronate Sodium Tablets

15 May 2019 Evaluate

Orchid Pharma is currently trading at Rs. 4.00, up by 0.17 points or 4.44% from its previous closing of Rs. 3.83 on the BSE.

The scrip opened at Rs. 4.00 and has touched a high and low of Rs. 4.00 and Rs. 4.00 respectively. So far 600 shares were traded on the counter.

The BSE group 'Z' stock of face value Rs. 10 has touched a 52 week high of Rs. 10.50 on 22-Jun-2018 and a 52 week low of Rs. 3.04 on 14-Feb-2019.

Last one week high and low of the scrip stood at Rs 4.72 and Rs. 3.83 respectively. The current market cap of the company is Rs. 34.07 crore.

The promoters holding in the company stood at 26.68%, while Institutions and Non-Institutions held 4.52% and 68.80% respectively.

Orchid has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg. Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.

Orchid Pharma Share Price

1104.95 5.40 (0.49%)
16-Apr-2024 14:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1535.45
Dr. Reddys Lab 6027.00
Cipla 1376.10
Zydus Lifesciences 942.45
Lupin 1605.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.